Currax Pharmaceuticals LLC Overview
Pro stress-test →Currax Pharmaceuticals is a specialty biopharmaceutical company dedicated to expanding patient access to clinically differentiated prescription medicines, primarily focused on obesity and smoking—the top two causes of preventable death in the U.S. The company's portfolio includes CONTRAVE®, the #1 prescribed branded oral weight-loss medication in the US, along with over 20 products including ONZETRA® Xsail®, Silenor®, and Treximet®.
Strategic Profile
Pro stress-test →In April 2026, Currax expanded patient access to CONTRAVE® through a partnership with Peek Healthcare Technologies via PeekDirect, which offers transparent, upfront pricing at the point of prescription. In March 2026, the company obtained FDA approval for a second manufacturing site for CONTRAVE® to meet rising demand for weight loss drugs. The company positions itself as a patient-first manufacturer leveraging direct-access models and expanded capacity to capture growing obesity treatment market share.
Competitive Landscape
Pro stress-test →Currax competes in the specialty pharma sector against companies targeting obesity, CNS disorders, and pain management. While dominant in branded oral weight-loss medications, the company faces competition from GLP-1 agonist manufacturers (Novo Nordisk, Eli Lilly) and other obesity treatment providers. The expanding obesity treatment market and Currax's first-mover advantage in non-GLP-1 branded oral medications position it favorably, though GLP-1 dominance represents a significant competitive headwind.
Industry Context
Currax Pharmaceuticals LLC operates in Specialty Pharmaceuticals / Obesity Treatment.
Key facts
Founded: 2019 · Headquarters: Brentwood, Tennessee, US · Employees: 150+